Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

7.43
-0.0550-0.74%
Volume:1.85M
Turnover:13.72M
Market Cap:1.84B
PE:-163.84
High:7.50
Open:7.47
Low:7.31
Close:7.48
52wk High:11.31
52wk Low:6.00
Shares:248.00M
Float Shares:218.00M
Volume Ratio:0.54
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0453
EPS(LYR):-0.4300
ROE:587.33%
ROA:10.31%
PB:-4.75
PE(LYR):-17.27

Loading ...

Earning Preview: Biocryst Pharmaceuticals’ this quarter’s revenue is expected to increase by 16.27%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 19

BioCryst resumed with an Outperform at Evercore ISI

TIPRANKS
·
Feb 18

BioCryst Pharmaceuticals to Present at T.D. Cowen Annual Health Care Conference

Reuters
·
Feb 17

BioCryst Unveils Positive New HAE Data for ORLADEYO and Navenibart at AAAAI 2026

Reuters
·
Feb 11

BioCryst Pharmaceuticals kündigt Veröffentlichung neuer Finanzergebnisse an

Reuters
·
Feb 05

BioCryst Grants Stock Options and RSUs to New Employees Under Inducement Plan

Reuters
·
Feb 05

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 05

RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating

MT Newswires Live
·
Jan 30

Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX)

TIPRANKS
·
Jan 30

BioCryst Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Jill C. Milne

Reuters
·
Jan 28

BioCryst Completes Acquisition of Astria Therapeutics

Reuters
·
Jan 26

BioCryst Pharmaceuticals Amends Board Appointment Disclosure

Reuters
·
Jan 24

Astria Therapeutics Shareholders Greenlight Acquisition by BioCryst Pharmaceuticals

MT Newswires Live
·
Jan 22

Astria Shareholders Approve Acquisition by BioCryst

Reuters
·
Jan 22

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jan 13

Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jan 13

GUIDANCE: (BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M

MT Newswires Live
·
Jan 12

BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million

Reuters
·
Jan 12

BioCryst Pharmaceuticals Inc: Expects Continued Non-Gaap Profitability in 2026

THOMSON REUTERS
·
Jan 12

BioCryst Announces Preliminary Full Year 2025 Orladeyo® (Berotralstat) Net Revenue of $601 Million (+37 Percent Y-O-Y), Beating Prior Guidance Range

THOMSON REUTERS
·
Jan 12